20,650
-0.72%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ilsung IS Co
Its shares trade on KRX under the ticker 003120.KS. It has been listed since 14 January 1985. In the fiscal year to 31 December 2025, it reported revenue of ₩64.29bn and net income of ₩1.17bn. At that date it held total assets of ₩403.01bn and shareholders' equity of ₩386.34bn.
Ilsung Pharmaceutical Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The firm distributes its products through wholesalers, hospitals, pharmacies and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Jan 1985
- Employees
- 239
- Website
- ilsung-ph.co.kr ↗
Leadership
Pay as last reported
- Mr. Seok Geun YoonChief Executive Officer, Director, since 2005₩840.0m
- Mr. Sang Eon ChoVice President
- Mr. Hong Wu LeeVice President
- Mr. Jong Wuk YoonManaging Director, since 2019
- Mr. Dae Hwan BaeManaging Director, since 2023
- Mr. Sang Hak KimManaging Director
- Mr. Yeong Min KimAssistant Managing Director, since 2021
- Mr. Jong Ho YoonAssistant Managing Director
- Mr. Seong Yeol LeeNon-Executive Independent Director
- Mr. Chang Wan SonNon-Executive Independent Director
- Mr. Seong Won YoonNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ilsung IS Co Ltd develops and sells penicillin antibiotics and cardiovascular drugs in South Korea.
- The company employs 239 full-time employees focused on pharmaceutical manufacturing and sales.
- Ilsung IS Co Ltd distributes products through hospitals, pharmacies, and wholesalers across South Korea.
Weaknesses
- Ilsung IS Co Ltd has limited product diversity beyond antibiotics and cardiovascular agents.
- The company's reliance on South Korea's domestic market restricts international expansion.
- Ilsung IS Co Ltd's product range lacks antivirals and anti-diabetics in key therapeutic areas.
Opportunities
- Ilsung IS Co Ltd can expand into the growing South Korean pharmaceutical market for cardiovascular drugs.
- The company can leverage its existing distribution network to enter new therapeutic segments.
- Ilsung IS Co Ltd can target the increasing demand for digestive drugs in South Korea.
Threats
- Ilsung IS Co Ltd faces competition from established pharmaceutical firms in South Korea.
- The company must comply with strict South Korean pharmaceutical regulations and standards.
- Ilsung IS Co Ltd's limited international presence exposes it to regional market volatility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.